Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186558 | 1.00 | TAAR1 (0.63) | TAAR1TDP1SLC6A3IDO1AGXT | |
| SCHEMBL79429 | 0.87 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL3371633 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL27821895 | 0.85 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL4469226 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL31035947 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL4427688 | 0.83 | TDP1 (0.65) | TAAR1TDP1DRD2MAOBALDH1A1 | |
| SCHEMBL30361126 | 0.81 | — | — | |
| SCHEMBL3830 | 0.81 | — | — | |
| SCHEMBL1538139 | 0.79 | TAAR1 (0.54) | TAAR1SLC6A3IDO1AGXTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119528906-A | Azaspiro compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025006262-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OMNIAB, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| EP-1023898-A1 | Cyano-indoles as serotonine reuptake inhibitors and as 5-HT2c receptor ligands | ADIR ET COMPAGNIE (FR) | 2000-08-02 | — | — | EP | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5973156-A | Piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOME LTD. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5889008-A | Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0861245-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| EP-0844996-A1 | SUBSTITUTED 1-INDOLYLPROPYL-4-PHENETHYLPIPERAZINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997006159-A1 | SUBSTITUTED 1-INDOLYLPROPYL-4-PHENETHYLPIPERAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | HIF1AN, HIF1A, EGLN2 | TAAR1 4781/4885TDP1 3192/4885SLC6A3 4514/4885 |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | TAAR1 630/4885TDP1 553/4885SLC6A3 4408/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | TAAR1 141/4885TDP1 395/4885SLC6A3 70/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | TAAR1 2444/4885TDP1 4092/4885SLC6A3 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.